Related Experiment Video
Updated: May 5, 2026

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
Published on: August 16, 2017
[Real-world data for comparative effectiveness research: Taking stock of available data sources in Germany with
Malik Cakir1, Paula Starke1, Alexandra Nolting2
1Institut für medizinische Statistik, Universitätsmedizin Göttingen (UMG), Göttingen, Deutschland.
Abstract:
Using real-world data (RWD) for comparative effectiveness research has gained increasing attention. Real-world data is usually not collected with the primary aim of answering questions about the comparative effectiveness of medical interventions. Therefore, data collection is often not optimally designed for this purpose. For this reason, using it can be associated with several data-related or analysis-related problems. This article has two aims: First of all, we will outline the basic requirements for comparative non-randomized studies based on RWD. In addition, the advantages and disadvantages of potentially eligible RWD in Germany will be considered. In particular, the use of registry data will be discussed, as these currently appear to be the most suitable for comparing the effectiveness of interventions. There are now various databases in Germany that contain RWD and can potentially be used for comparative effectiveness research. If they contain all the necessary information and if the data are of sufficient quality, they could offer a timely and efficient way of determining the effectiveness of medical interventions. However, our analysis shows that the use of this data is sometimes associated with considerable limitations. RWD is often highly aggregated and thus may not be sufficiently detailed to select the subjects precisely or to emulate the intervention or control interventions satisfactorily. In addition, many data sources only encompass a limited set of variables and limited time horizons (e.g., only hospitalization) according to their intended purpose (e.g., billing). Therefore, it is often questionable whether this includes all endpoints on benefit and harm that are important for the assessment and whether sufficiently long observation horizons/follow-up periods are given. Similarly, it is often questionable whether all necessary data to avoid bias are included. Furthermore, it is often difficult to assess suitability in advance due to the lack of available information.
More Related Videos
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
09:00TBase - an Integrated Electronic Health Record and Research Database for Kidney Transplant Recipients
Published on: April 13, 2021
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Bioequivalence Data: Statistical Interpretation
Dosage Regimens: Partial Pharmacokinetic Parameters
Comparing the Survival Analysis of Two or More Groups
Hazard Ratio
For example, in a clinical trial...